Cytokinetics booked its first full quarter of MYQORZO sales on Aug. 6. Armistice Capital used the same three months to raise its stake in the company, at a time when several biopharma-focused hedge funds were absorbing losses on concentrated bets elsewhere in the industry.
MYQORZO’s First Full Quarter
Cytokinetics reported $25.3 million in net product revenue from MYQORZO, its therapy for symptomatic obstructive hypertrophic cardiomyopathy, in the three months ended June 30. The United States accounted for $23 million of that total and Europe for $2.3 million, a figure inflated by initial stocking for the German launch rather than by underlying demand. More than 700 health care providers had prescribed the drug by quarter’s end, and roughly 1,500 patients had received it, with more than 80 percent of them still on therapy.
The drug, known chemically as aficamten, has also launched in the United Kingdom and China since its Dec. 19, 2025, U.S. approval, and regulators in Canada, Switzerland, Hong Kong and Taiwan are reviewing it. Cytokinetics has filed 10 health technology assessment packages with European regulators, with additional launches planned in more than five markets before mid-2027. Total company revenue fell to $28.6 million from $66.8 million a year earlier, a decline tied to a drop in collaboration payments rather than to the commercial launch itself. Chief Executive Robert Blum said, “Our second quarter results demonstrate commercial launch momentum for MYQORZO alongside continued excellence for our development pipeline.”
